P53 regulates LIF expression in human medulloblastoma cells

Journal of Neuro-Oncology

Volumn 97, Issue 3, 2010, Pages 373-382

  Baxter, Euan W ^a   Milner, Jo ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Apoptosis; LIF; Medulloblastoma; P53; SIRT1; WIP1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; LEUKEMIA INHIBITORY FACTOR; MUTANT PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN P53; SIRTUIN 1; SMALL INTERFERING RNA; LIF PROTEIN, HUMAN; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C; SIRT1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN STABILITY; RNA INTERFERENCE; WILD TYPE; DRUG EFFECT; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA INHIBITORY FACTOR; MEDULLOBLASTOMA; PHOSPHOPROTEIN PHOSPHATASES; PROTEIN BINDING; RNA, SMALL INTERFERING; SIRTUIN 1; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953286680     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0043-x     Document Type: Article

References (32)

1. Gilbertson RJ (2004) Medulloblastoma: signalling a change in treatment. Lancet Oncol 5:209-218
2. Liu J, Gang Y, Guo L, Li H (1999) Expression of leukemiainhibitory factor as an autocrinal growth factor in human medulloblastomas. J Cancer Res Clin Oncol 125:475-480
3. Williams RL, Hilton DJ, Pease S, Willson TA, Stewart CL, Gearing DP, Wagner EF, Metcalf D, Nicola NA, Gough NM (1988) Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336: 684-687
4. Bauer S, Patterson PH (2006) Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci 26:12089-12099
5. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC (2008) PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22:436-448
6. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432:396-401
7. Nichols J, Davidson D, Taga T, Yoshida K, Chambers I, Smith A (1996) Complementary tissue-specific expression of LIF and LIFreceptor RNAs in early mouse embryogenesis. Mech Dev 57: 123-131
8. Hu W, Feng Z, Teresky AK, Levine AJ (2007) p53 regulates maternal reproduction through LIF. Nature 450:721-724
9. Auernhammer CJ, Melmed S (2000) Leukemia-inhibitory factor- neuroimmune modulator of endocrine function. Endocr Rev 21:313-345
10. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R (2008) Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther 7:3519-3526
11. Haines BP, Voyle RB, Pelton TA, Forrest R, Rathjen PD (1999) Complex conserved organization of the mammalian leukemia inhibitory factor gene: regulated expression of intracellular and extracellular cytokines. J Immunol 162:4637-4646
12. Rathjen PD, Toth S, Willis A, Heath JK, Smith AG (1990) Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage. Cell 62:1105-1114
13. Haines BP, Voyle RB, Rathjen PD (2000) Intracellular and extracellular leukaemia inhibitory factor proteins have different cellular activities that are mediated by distinct protein motifs. Mol Biol Cell 11:1369-1383
14. Adesina AM, Nalbantoglu J, Cavanee WK (1994) p53 gene mutation and mdm2 amplification are uncommon in medulloblastoma. Cancer Res 54:5649-5651
15. Castellino RC, De Bartoli M, Lu X, Moon S-H, Nguyen T-A, Shepard MA, Rao PH, Donehower LA (2008) Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 86:245-256
16. Lu X, Nguyen T-A, Moon S-H, Darlington Y, Sommer M, Donehower LA (2008) The type 2C phosphatase WIP1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 27:123-135
17. Brooks CL, Gu W (2003) Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 15:164-171
18. Parssinen J, Alarmo EL, Karhu R, Kallioniemi A (2008) PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cells with wild-type p53. Cancer Genet Cytogenet 182:33-39
19. Michael D, Oren M (1992) The p53 and Mdm2 families in cancer. Curr Opin Genet Dev 12:53-59
20. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, Guarente L, Gu W (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107:137-148
21. Vaziri H, Dessain SK, Ng Eaton E, Imai S, Frye RA, Pandita TK, Guarente L, Weinberg RA (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159
22. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, Pelicci PG, Kouzarides T (2002) Human SIR2 deacetylates p53 and antagonises PML/p53-induced cellular senescence. EMBO J 21:2383-2396
23. Ford J, Jiang M, Milner J (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65:10457-10463
24. Zhang Q, Wang S-Y, Fleuriel C, Leprince D, Rocheleau JV, Piston DW, Goodman RH (2007) Metabolic regulation of SIRT1 transcription via a HIC1:CtBPcorepressor complex. Proc Natl Acad Sci (USA) 104:829-833
25. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson ADJ, Ellison DW, Clifford SC (2004) Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 25:661-668
26. Saylors RLI, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B, Brodeur GM (1991) Infrequent p53 gene mutations in medulloblastoma. Cancer Res 51:4721-4723
27. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Investig 104:263-269
28. Fujimoto H, Onishi N, Kato N, Takekawa M, Xu X, Kosugi A, Kondo T, Imamura M, Oishi I, Yoda A, Minami Y (2006) Regulation of the antioncogenic Chk2 kinase b the oncogenic Wip1 phosphatase. Cell Death Differ 13:1170-1180
29. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JY (2007) Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 7:127-142
30. Briggs KJ, Corcoran-Schwartz IM, Zhang W, Harcke T, Devereux WL, Baylin SB, Eberhart CG, Watkins DN (2008) Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma. Genes Dev 22:770-785
31. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ Jr (2004) Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)- p19(Arf) pathway. Nature Genet 36(4):319-320
32. Alcain FJ, Villalba JM (2009) Sirtuin inhibitors. Expert Opin Ther Pat 19(3):283-294